Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 19/20 | 0.78 |
| ▸ | CCR5 | P51681 | 11/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.69 |
| ▸ | CCR1 | P32246 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299192 | 0.91 | CCR2 (0.70) | CCR2CCR5KCNH2CCR1TMEM97 | |
| SCHEMBL3325663 | 0.90 | CCR2 (0.77) | CCR2CCR5KCNH2 | |
| SCHEMBL14011030 | 0.90 | CCR2 (0.77) | CCR2CCR5KCNH2 | |
| SCHEMBL18259123 | 0.90 | CCR2 (0.77) | CCR2CCR5KCNH2 | |
| SCHEMBL4141218 | 0.88 | CCR2 (0.64) | CCR2CCR5KCNH2CCR1TMEM97 | |
| SCHEMBL6015055 | 0.88 | CCR2 (0.64) | CCR2CCR5KCNH2CCR1TMEM97 | |
| SCHEMBL13741551 | 0.88 | CCR2 (0.64) | CCR2CCR5KCNH2CCR1TMEM97 | |
| SCHEMBL4102147 | 0.88 | CCR2 (0.80) | CCR2CCR5KCNH2CCR1TMEM97 | |
| SCHEMBL4138164 | 0.87 | CCR2 (1.00) | CCR2CCR5KCNH2 | |
| SCHEMBL13613397 | 0.87 | CCR2 (1.00) | CCR2CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618970-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2009-11-17 | — | — | US | claimed |
| US-8563582-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563582-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563582-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-7618970-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618970-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2009-08-20 | — | — | US | disclosed |
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2009-08-20 | — | — | US | disclosed |
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | CCR2 4/4885CCR5 1/4885KCNH2 3779/4885 |
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | CCR2 4/4885CCR5 1/4885KCNH2 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.